細胞裂解市場 - 全球產業規模、佔有率、趨勢、機會、預測：按產品類型、細胞類型、最終用戶、地區和競爭格局分類，2021-2031年

全球細胞裂解市場預計將經歷顯著成長，從 2025 年的 33.4 億美元成長到 2031 年的 53.1 億美元，複合年成長率為 8.03%。

細胞裂解是破壞細胞膜、釋放細胞內成分（如DNA、RNA和蛋白質）的關鍵過程，也是分​​離生物學、基因組學和蛋白​​質組學研究取得重大進展的基礎步驟。推動市場擴張的主要因素包括全球對生物製藥日益成長的需求以及精準醫療的快速發展，這兩者都需要提取高品質的樣本進行後續分析。此外，感染疾病和慢性病發病率的上升也推動了對可靠診斷檢測方法的需求。產業對創新的巨額投資也支撐了這一成長，例如，歐洲製藥業在2025年前一年的研發支出預計將達到550億歐元。儘管前景光明，市場也面臨挑戰。特別是，先進的自動化裂解設備的高成本和技術複雜性可能會阻礙小規模研究機構的廣泛應用。此外，生物檢體的多樣性也為方案標準化帶來了技術障礙，可能導致實驗結果的差異。

市場促進因素

全球細胞裂解市場的主要驅動力是慢性病和感染疾病在全球範圍內的日益流行，這需要更完善的診斷和研究流程。癌症等疾病負擔日益加重，預計到2025年美國新增病例將超過200萬例，這增加了對分子診斷和生物標記發現流程的需求，而這些流程高度依賴高效的細胞裂解來提取高品質的遺傳物質和蛋白質。這一趨勢迫使臨床檢查室增加裂解試劑的消耗量，以處理精準腫瘤學中不斷成長的檢體量。同時，生命科學研究領域公共和私人資金的增加也提供了重要的資金支持。政府撥款，例如美國國會為2025財政年度向美國國立衛生研究院（NIH）累計約485億美元，是學術機構和私人公司採用先進樣本製備設備的重要資金來源。這項資金支持了生命科學工具的廣泛生態系統，並凸顯了對下游分析所必需的實驗室產品的強勁需求，這體現在賽默飛世爾科技公司 2024 年 428.8 億美元的銷售額中。

市場挑戰

由於先進的自動化裂解設備高成本且技術複雜，全球細胞裂解市場面臨許多挑戰。大型製藥企業能夠承擔這些巨額成本，但小規模的學術機構和新興研究機構往往缺乏高通量系統所需的資金，這限制了自動化解決方案的普及。這種經濟差距迫使許多小規模機構繼續使用低通量、人工操作且勞動密集的方法，導致相當一部分潛在用戶無法獲得先進技術，從而阻礙了市場進一步滲透。小規模機構面臨的嚴峻資金籌措環境進一步加劇了這個問題，有限的資源限制了實驗室基礎設施的重大升級。例如，2025年第一季和第二季度，生技新創公司的資金籌措從26億美元驟降至9億美元。這種財務壓力，加上標準化不同樣本類型操作流程的技術挑戰，導致營運效率參差不齊，最終減緩了整體市場成長速度。

市場趨勢

目前，兩大關鍵趨勢正在重塑全球細胞裂解市場。首先，用於多體學分析的單細胞裂解技術的進步，正將研究重點從組織整體處理轉向從單一細胞中精確提取細胞內成分。這項轉變對於闡明腫瘤學和免疫學等領域的細胞異質性至關重要，需要專門的、溫和的裂解方案，以保護微量RNA和蛋白質免受分解。這些高解析度工作流程的日益普及，推動了專注於微流體和液滴裂解技術的細分市場的成長，而這些技術對於多體學研究的上游工程樣品製備至關重要。這項轉變的商業性影響在10x Genomics公司2024年全年銷售額達到6.108億美元中可見一斑，反映了業界對依賴這些先進裂解方法的單細胞平台的持續需求。其次，自動化、高通量裂解系統的普及正在改變實驗室，以標準化的機器人平台取代人工破碎技術，旨在提高實驗的可重複性和處理速度。隨著生物樣本庫和臨床研究中心需要處理日益成長的樣本量，自動化系統正逐漸成為主流。這些系統將溶解、結合和洗滌步驟整合到一個無縫的「無人值守」流程中，從而最大限度地減少人為錯誤和交叉污染。這種轉變正在加速專用樣本製備系統的應用，這些系統能夠處理從血液到組織等多種基質。 Qiagen 的 EZ2 Connect 自動化樣本製備系統已完成超過 1000 台的安裝，充分展現了市場對整合式溶解自動化解決方案的強勁需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球細胞裂解市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品類型（儀器{均質機、離心機、其他產品類型}、試劑），
  • 細胞類型（哺乳動物細胞、微生物細胞、植物細胞）
  • 按最終用戶分類（生物技術和生物製藥公司、研究機構和學術機構以及其他最終用戶）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美細胞裂解市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲細胞裂解市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區細胞裂解市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲細胞裂解市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美細胞裂解市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球細胞裂解市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• Eppendorf AG
• Hoffmann-La Roche Ltd
• Labfreez Instruments Group Co. Ltd
• Merck KGaA
• Qsonica LLC
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Cell Lysis Market is projected for substantial growth, expanding from USD 3.34 Billion in 2025 to USD 5.31 Billion by 2031, demonstrating an 8.03% CAGR. Cell lysis, defined as the essential process of rupturing cell membranes to liberate intracellular components like DNA, RNA, and proteins, is a foundational step for critical advancements in molecular biology, genomics, and proteomics research. Key drivers for this market expansion include the increasing global demand for biopharmaceuticals and the rapid evolution of precision medicine, both requiring high-quality sample extraction for subsequent analysis. Furthermore, the rising incidence of infectious and chronic diseases fuels the demand for robust diagnostic assays. This growth is underpinned by significant industry investment in innovation, as evidenced by the European pharmaceutical sector's estimated €55 billion R&D expenditure in Europe during the year preceding 2025. Despite this positive outlook, the market faces challenges, particularly the high cost and technical complexity of advanced automated lysis instrumentation, which can impede widespread adoption by smaller research facilities. Additionally, the diverse nature of biological samples presents technical hurdles in standardizing protocols, potentially leading to inconsistent experimental outcomes.

Market Driver

The primary catalyst driving the Global Cell Lysis Market is the escalating worldwide prevalence of chronic and infectious diseases, which mandates more robust diagnostic and research workflows. The growing burden of conditions like cancer, projected to exceed 2 million new cases in the U.S. in 2025, intensifies the need for molecular diagnostics and biomarker discovery-processes heavily reliant on efficient cell lysis for extracting high-quality genetic material and proteins. This trend compels clinical laboratories to increase their consumption of lysis reagents to manage the expanding volume of samples for precision oncology. Concurrently, a significant financial impetus comes from increased public and private funding in life sciences research. Government allocations, such as the U.S. Congress enacting approximately $48.5 billion for the National Institutes of Health in fiscal year 2025, provide crucial capital for academic and commercial entities to acquire sophisticated sample preparation instrumentation. This funding supports the broader ecosystem of life science tools, as reflected by Thermo Fisher Scientific's 2024 revenue of $42.88 billion, underscoring the strong demand for laboratory products essential for downstream analyses.

Market Challenge

The Global Cell Lysis Market faces a significant obstacle in the high cost and intricate technical nature of advanced automated lysis instrumentation. While large pharmaceutical corporations can absorb these substantial expenses, smaller academic and emerging research facilities frequently lack the necessary capital for high-throughput systems, thus limiting the widespread adoption of automated solutions. This economic disparity forces many smaller institutions to continue using manual, labor-intensive methods that offer lower throughput, creating an adoption gap where advanced technology remains inaccessible to a substantial segment of potential users and hinders broader market penetration. Compounding this issue is a challenging funding environment for smaller entities, with constrained financial resources preventing crucial upgrades to laboratory infrastructure. For example, biotech startup funding saw a significant decline from $2.6 billion to $900 million between Q1 and Q2 2025. This financial pressure, coupled with the technical difficulties of standardizing protocols across varied sample types, results in inconsistent operational efficiencies and ultimately dampens the market's overall growth trajectory.

Market Trends

Two pivotal trends are currently reshaping the Global Cell Lysis Market. First, advancements in Single-Cell Lysis for Multi-Omics Analysis are driving a shift from bulk tissue processing to the precise extraction of intracellular contents from individual cells. This evolution is vital for unraveling cellular heterogeneity in fields such as oncology and immunology, demanding specialized, gentle lysis protocols that protect minute quantities of RNA and protein from degradation. The increasing adoption of these high-resolution workflows has spurred a dedicated segment for microfluidic and droplet-based lysis technologies, crucial for upstream sample preparation in multi-omics studies. The commercial impact of this shift is evident in 10x Genomics' full-year 2024 revenue of $610.8 million, reflecting sustained industrial demand for single-cell platforms reliant on these advanced lysis methods. Second, the proliferation of Automated High-Throughput Lysis Systems is transforming laboratories by replacing manual disruption techniques with standardized, robotic platforms designed to enhance reproducibility and processing speed. As biobanks and clinical research centers manage growing sample volumes, there is a clear migration toward automated instruments that integrate lysis, binding, and washing steps into seamless "walk-away" protocols, thereby minimizing human error and cross-contamination. This transition is accelerating the installation of dedicated sample preparation units capable of processing diverse matrices, from blood to tissue. Qiagen's achievement of over 1,000 placements of its EZ2 Connect automated sample preparation instrument validates the robust market uptake of integrated lysis automation solutions.

Key Market Players

• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• Eppendorf AG
• Hoffmann-La Roche Ltd
• Labfreez Instruments Group Co. Ltd
• Merck KGaA
• Qsonica LLC
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global Cell Lysis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Lysis Market, By Type of Product

• Instruments
• Reagents

Cell Lysis Market, By Type of cells

• Mammalian Cells
• Microbial Cells
• Plant Cells

Cell Lysis Market, By End user

• Biotechnology or Biopharmaceutical Companies
• Research Laboratories and Academic Institutes
• Other End Users

Cell Lysis Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Lysis Market.

Available Customizations:

Global Cell Lysis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Lysis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Product (Instruments {Homogeniser, Centrifugation, Other Types of Products}, Reagents)
  • 5.2.2. By Type of cells (Mammalian Cells, Microbial Cells, Plant Cells)
  • 5.2.3. By End user (Biotechnology or Biopharmaceutical Companies, Research Laboratories and Academic Institutes, Other End Users)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Cell Lysis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Product
  • 6.2.2. By Type of cells
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell Lysis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Product
      • 6.3.1.2.2. By Type of cells
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Cell Lysis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Product
      • 6.3.2.2.2. By Type of cells
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Cell Lysis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Product
      • 6.3.3.2.2. By Type of cells
      • 6.3.3.2.3. By End user

7. Europe Cell Lysis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Product
  • 7.2.2. By Type of cells
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell Lysis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Product
      • 7.3.1.2.2. By Type of cells
      • 7.3.1.2.3. By End user
  • 7.3.2. France Cell Lysis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Product
      • 7.3.2.2.2. By Type of cells
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Cell Lysis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of Product
      • 7.3.3.2.2. By Type of cells
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Cell Lysis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Product
      • 7.3.4.2.2. By Type of cells
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Cell Lysis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Product
      • 7.3.5.2.2. By Type of cells
      • 7.3.5.2.3. By End user

8. Asia Pacific Cell Lysis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Product
  • 8.2.2. By Type of cells
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell Lysis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Product
      • 8.3.1.2.2. By Type of cells
      • 8.3.1.2.3. By End user
  • 8.3.2. India Cell Lysis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Product
      • 8.3.2.2.2. By Type of cells
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Cell Lysis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Product
      • 8.3.3.2.2. By Type of cells
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Cell Lysis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Product
      • 8.3.4.2.2. By Type of cells
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Cell Lysis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Product
      • 8.3.5.2.2. By Type of cells
      • 8.3.5.2.3. By End user

9. Middle East & Africa Cell Lysis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Product
  • 9.2.2. By Type of cells
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell Lysis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Product
      • 9.3.1.2.2. By Type of cells
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Cell Lysis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Product
      • 9.3.2.2.2. By Type of cells
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Cell Lysis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Product
      • 9.3.3.2.2. By Type of cells
      • 9.3.3.2.3. By End user

10. South America Cell Lysis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Product
  • 10.2.2. By Type of cells
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell Lysis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Product
      • 10.3.1.2.2. By Type of cells
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Cell Lysis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Product
      • 10.3.2.2.2. By Type of cells
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Cell Lysis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Product
      • 10.3.3.2.2. By Type of cells
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell Lysis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Becton, Dickinson and Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bio-Rad Laboratories Inc.
• 15.3. Danaher Corporation
• 15.4. Eppendorf AG
• 15.5. Hoffmann-La Roche Ltd
• 15.6. Labfreez Instruments Group Co. Ltd
• 15.7. Merck KGaA
• 15.8. Qsonica LLC
• 15.9. Takara Bio Inc.
• 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer